ReviewActa dermato-venereologica2026
Redefining Treat-to-target in Atopic Dermatitis: Towards Meaningful, Patient-centred Disease Control - An ISAD Position Paper.
Review in Acta dermato-venereologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treat-to-target strategies link predefined goals to regular assessment and treatment adaptation. In atopic dermatitis, recent initiatives have mainly defined thresholds using clinician- and patient-reported outcomes. This review and position paper critically examines current approaches and proposes priorities for a more clinically meaningful, patient-centred and globally applicable framework. It synthesizes recent consensus and outcome-harmonization initiatives with selected lessons from rheumatoid arthritis and asthma and was informed by multidisciplinary, patient-inclusive discussions at an International Society of Atopic Dermatitis-World Health Organization premeeting. The workshop was not a Delphi or formal consensus exercise; it was used to identify conceptual priorities and implementation challenges for future international consensus work. Current proposals converge partly around severity thresholds and symptom control but insufficiently capture disease instability, comorbidities, family burden, treatment burden and real-world constraints. We propose 4 complementary domains: disease activity; symptoms and function; global patient health and disease impact and longitudinal control and treatment adaptation. Some components are supported by validated measures, whereas others remain exploratory. Treat-to-target in atopic dermatitis should evolve beyond isolated thresholds towards an adaptable multidimensional strategy, followed by formal international consensus and prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.